Parkin et al. Ca cancer j clin. 2005;55: 74-108. Parkin et al. Ca cancer j clin. 2005;55: 74-108
Yüklə
450 b.
tarix
05.03.2018
ölçüsü
450 b.
#29658
Bu səhifədəki naviqasiya:
Surgery and carboplatin-paclitaxel iv are the cornerstones of first-line therapy
Long-term remission dependent upon surgical/chemotherapy approach
Patient/disease factors – heterogeneous disease
E. Pujade-Lauraine et al.
Gadducci et al. Anticancer Res . 2001;21:3525-3533.
Cure
Maintenance of quality of life (tend to correlate with response rate)
Parkin et al.
CA Cancer J Clin.
2005;55:74-108.
Parkin et al.
CA Cancer J Clin.
2005;55:74-108.
Surgery and carboplatin-paclitaxel iv are the cornerstones
of first-line therapy
Surgery and carboplatin-paclitaxel iv are the cornerstones of first-line therapy
80%-85% respond to first-line therapy
Newer regimens including molecular targeted therapy
are under investigation
Most patients develop disease recurrence within 2 years of diagnosis
Long-term remission dependent upon surgical/chemotherapy approach
Several agents active
in the second-line setting
, resulting in improved progression-free and overall survival
Patient/disease factors –
heterogeneous disease
Patient/disease factors – heterogeneous disease
Prior complete debulking or initial FIGO I/II
Ascites > 500ml
Performance status ECOG 0
Age
Presence/absence
of symptoms
Platin-based chemotherapy
Parenchymal
involvement
Relapse-free vs treatment-free interval (TFI)
Patient/disease factors – heterogeneous disease
Patient/disease factors – heterogeneous disease
Prior complete debulking or initial FIGO I/II
Ascites > 500ml
Performance status ECOG 0
Age
Presence/absence of symptoms
Platin-based chemotherapy
Parenchymal involvement
Relapse-free vs treatment-free interval (TFI)
E. Pujade-Lauraine et al.
E. Pujade-Lauraine et al.
Gadducci et al.
Anticancer Res
. 2001;21:3525-3533.
Gadducci et al.
Anticancer Res
. 2001;21:3525-3533.
Bookman.
The
Oncologist
. 1999;4:87-94.
Bookman.
The Oncologist
. 1999;4:87-94.
Cure
Cure
Survival prolongation
Achievement
of durable objective response
Improvement in cancer-related symptoms
Maintenance of quality of life (tend to correlate with response rate)
Delayed time to (symptomatic) disease progression
Yüklə
450 b.
Dostları ilə paylaş:
Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©genderi.org 2024
rəhbərliyinə müraciət
Ana səhifə
Psixologiya